Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Tumor Immunotherapy01:27

Tumor Immunotherapy

475
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
475
T Cell Activation and Clonal Selection01:22

T Cell Activation and Clonal Selection

655
T cells are integral to our adaptive immune system, recognizing and effectively responding to foreign antigens. T cell activation and clonal selection are pivotal in orchestrating this immune response. This article elucidates these mechanisms, detailing the roles of cluster of differentiation (CD) markers, major histocompatibility complex (MHC) molecules, costimulatory signals, and the process of clonal selection.
Naive T cells that have not yet encountered an antigen express two primary CD...
655

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

CircAI: a comprehensive database of CircRNA associated with A-to-I RNA editing.

Database : the journal of biological databases and curation·2025
Same author

TMBclaw: tumor clone-aware graph learning improves immunotherapy response prediction across heterogeneous cohorts.

Briefings in bioinformatics·2025
Same author

Stereoselective synthesis of 1,4-diols by a tandem allylboration-allenylboration sequence.

Organic letters·2015
Same author

The effect of lactic acid bacteria on cocoa bean fermentation.

International journal of food microbiology·2015
Same author

The performance of a combined nitritation-anammox reactor treating anaerobic digestion supernatant under various C/N ratios.

Journal of environmental sciences (China)·2015
Same author

Cytotoxicity profile of novel sterically hindered platinum(II) complexes with (1R,2R)-N(1),N(2)-dibutyl-1,2-diaminocyclohexane.

European journal of medicinal chemistry·2015

相关实验视频

Updated: Jun 5, 2025

Predictive Immune Modeling of Solid Tumors
08:50

Predictive Immune Modeling of Solid Tumors

Published on: February 25, 2020

6.9K

索尔:一个TMB异质性适应性优化模型预测使用克隆基因组特征在群组结构数据中的免疫治疗反应.

Yixuan Wang1, Yanfang Guan2,3, Xin Lai2

  • 1Department of Biomedical Engineering, College of Automation Engineering, Nanjing University of Aeronautics and Astronautics, 29 Jiangjun Avenue, Jiangning, Nanjing 211106, China.

Briefings in bioinformatics
|December 16, 2024
PubMed
概括

瘤突变负担 (TMB) 是一个重要的癌症生物标志物,但它不能完全捕捉瘤的复杂性. 一个新的模型,THOR,整合了瘤克隆性和子组数据,以改善患者分层和免疫治疗的预后预测.

关键词:
癌症免疫疗法免疫疗法终点集成终点集成按组结构的数据数据.处罚的融合战略被处罚预后生物标志物 预后生物标志物瘤克隆异质性的异质性

更多相关视频

Comparative Lesions Analysis Through a Targeted Sequencing Approach
08:16

Comparative Lesions Analysis Through a Targeted Sequencing Approach

Published on: November 5, 2019

6.7K
Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids
08:52

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

Published on: November 22, 2021

3.9K

相关实验视频

Last Updated: Jun 5, 2025

Predictive Immune Modeling of Solid Tumors
08:50

Predictive Immune Modeling of Solid Tumors

Published on: February 25, 2020

6.9K
Comparative Lesions Analysis Through a Targeted Sequencing Approach
08:16

Comparative Lesions Analysis Through a Targeted Sequencing Approach

Published on: November 5, 2019

6.7K
Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids
08:52

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

Published on: November 22, 2021

3.9K

科学领域:

  • 在瘤学瘤学.
  • 免疫治疗是一种免疫疗法.
  • 生物信息学是一种生物信息学.

背景情况:

  • 免疫检查点抑制剂 (ICI) 越来越多地用于各种癌症.
  • 瘤突变负担 (TMB) 是ICI反应的生物标志物,但其临床实用性受到瘤复杂性的限制.
  • 现有的方法与小型免疫疗法试验队伍和复杂的瘤生物学作斗争.

研究的目的:

  • 开发一种先进的生物标志物模型,克服TMB的局限性.
  • 改善癌症免疫治疗的患者分层和预后预测.
  • 整合瘤克隆性和子组动态,以提高预测能力.

主要方法:

  • 介绍TMB异质性优化回归 (THOR) 模型.
  • 索尔集成瘤克隆性,多样化的临床终点,和子组特定的动态.
  • 使用跨子组的融合技术来进行强大的数据共享和解释.

主要成果:

  • 模拟证实了THOR对于统计推断的优越参数估计.
  • 在238名患者的队列中,THOR证明了患者分层的增强.
  • 对19个子组2212名患者的分析表明,THOR显著改善了预后预测.

结论:

  • 通过考虑瘤异质性和亚组变异,THOR提高了TMB的预测能力.
  • 该模型在癌症免疫治疗中提供了改善的患者分层和预后准确性.
  • 在利用复杂的免疫遗传数据为临床决策方面,THOR代表了重大进展.